COVID-19 Vaccines in the Pediatric Population: A Focus on Cardiac Patients

Overview

Journal Can J Infect Dis Med Microbiol

Publisher Wiley

Date 2024 May 23

PMID 38779616

Authors

Ghena Lababidi

Hossam Lababidi

Fadi Bitar

Mariam Arabi

Affiliations

Soon will be listed here.

Abstract

Due to the deleterious global impact of the COVID-19 pandemic, tremendous effort has been invested in the development of vaccines against the virus. Vaccine candidates are first tested in adult populations, a number of which have been approved for EUL by the WHO, and are in use across the USA and MENA region. The question remains whether these (or other) vaccines should be recommended to a neonatal, pediatric, and/or adolescent cohort. Incidence and severity of COVID-19 infection are low in pediatric, neonatal, and adolescent patients. Since both overall incidence and severity are lower in children than in adults, safety is an important consideration in vaccine approval for these age groups, in addition to efficacy and a decreased risk of transmission. The following review discusses vaccine immunology in children aged 0-18 years, with emphasis on the negative impact of the COVID-19 pandemic on the lives of children, considerations for pediatric vaccine approval, and available vaccines for pediatric cohorts along with a breakdown of the efficacy, advantages, and disadvantages for each. This review also contains current and future perspectives, as well as a section on the cardiovascular implications and related dynamics of pediatric COVID-19 vaccination.

References

Zona S, Partesotti S, Bergomi A, Rosafio C, Antodaro F, Esposito S . Anti-COVID Vaccination for Adolescents: A Survey on Determinants of Vaccine Parental Hesitancy. Vaccines (Basel). 2021; 9(11). PMC: 8618373. DOI: 10.3390/vaccines9111309. View

Simpson M, Collins C, Nash D, Panesar L, Oster M . Coronavirus Disease 2019 Infection in Children with Pre-Existing Heart Disease. J Pediatr. 2020; 227:302-307.e2. PMC: 7384421. DOI: 10.1016/j.jpeds.2020.07.069. View

Zaveri P, Clark S, Kan K, Lee B, Naik V, Opel D . Rapid Development and Testing of a COVID-19 Vaccine Curriculum for Pediatricians. Acad Pediatr. 2022; 23(4):790-799. PMC: 9479378. DOI: 10.1016/j.acap.2022.09.010. View

Luxi N, Giovanazzi A, Capuano A, Crisafulli S, Cutroneo P, Fantini M . COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 2021; 44(12):1247-1269. PMC: 8569292. DOI: 10.1007/s40264-021-01131-6. View

Kest H, Kaushik A, Shaheen S, Debruin W, Zaveri S, Colletti M . Epidemiologic Characteristics of Adolescents with COVID-19 Disease with Acute Hypoxemic Respiratory Failure. Crit Care Res Pract. 2022; 2022:7601185. PMC: 9467822. DOI: 10.1155/2022/7601185. View

Jain S, Venkataraman A, Wechsler M, Peppas N . Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv Drug Deliv Rev. 2021; 179:114000. PMC: 8502079. DOI: 10.1016/j.addr.2021.114000. View

Wati D, Manggala A . Overview of management of children with COVID-19. Clin Exp Pediatr. 2020; 63(9):345-354. PMC: 7462825. DOI: 10.3345/cep.2020.00913. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Cooper D, Afghani B, Byington C, Cunningham C, Golub S, Lu K . SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges. Pediatr Res. 2021; 90(5):966-970. PMC: 7903864. DOI: 10.1038/s41390-021-01402-z. View

10.

Peng H, Gao P, Xu Q, Liu M, Peng J, Wang Y . Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes. J Clin Virol. 2020; 128:104425. PMC: 7204737. DOI: 10.1016/j.jcv.2020.104425. View

11.

Frenck Jr R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S . Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385(3):239-250. PMC: 8174030. DOI: 10.1056/NEJMoa2107456. View

12.

Shi Q, Wang Z, Liu J, Wang X, Zhou Q, Li Q . Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 41:101155. PMC: 8523335. DOI: 10.1016/j.eclinm.2021.101155. View

13.

Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S . SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J. 2022; 19(1):144. PMC: 9452867. DOI: 10.1186/s12985-022-01873-4. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

15.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

16.

Zheng F, Liao C, Fan Q, Chen H, Zhao X, Xie Z . Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020; 40(2):275-280. PMC: 7095065. DOI: 10.1007/s11596-020-2172-6. View

17.

Dunay G, Barroso M, Woidy M, Danecka M, Engels G, Hermann K . Long-Term Antibody Response to SARS-CoV-2 in Children. J Clin Immunol. 2022; 43(1):46-56. PMC: 9483535. DOI: 10.1007/s10875-022-01355-w. View

18.

Ygberg S, Nilsson A . The developing immune system - from foetus to toddler. Acta Paediatr. 2011; 101(2):120-7. DOI: 10.1111/j.1651-2227.2011.02494.x. View

19.

Fleming-Dutra K, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi E . Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022; 327(22):2210-2219. PMC: 9107063. DOI: 10.1001/jama.2022.7493. View

20.

Saso A, Kampmann B . Vaccine responses in newborns. Semin Immunopathol. 2017; 39(6):627-642. PMC: 5711983. DOI: 10.1007/s00281-017-0654-9. View